
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
Coverage of the European Society for Medical Oncology Congress 2023, which took place in Madrid, Spain.






